한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제19권2호
  • /
  • Pages.153-158
  • /
  • 2009
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

만성골수성백혈병 환자의 효용가중치 비교

Comparison of Chronic Myeloid Leukemia Patient's Utility Weights

  • 이지현 (숙명여자대학교 임상약학대학원) ;
  • 이의경 (숙명여자대학교 임상약학대학원)
  • Lee, Ji-Hyeon (Graduate School of Clinical pharmacy, Sookmyung Women's University) ;
  • Lee, Eui-Kyung (Graduate School of Clinical pharmacy, Sookmyung Women's University)
  • 투고 : 2009.10.05
  • 심사 : 2009.12.21
  • 발행 : 2009.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Patients with chronic myeloid leukemia(CML) have different health status according to their disease conditions such as chronic phase(CP), accelerated phase(AP), blast crisis(BC), stage with MCyR(Major Cytogenetic Response); therefore, every patient has different quality of life related to their disease condition. Objectives: To measure the quality of life, this study compared and analyzed the utility weight in patients with CML. This study also evaluated the utility weight in order to view comparisons between the quality of life in a patient with CML to a patient with diabetes, which is a representative chronic disease. Methods: The disease scenario described 5 symptoms of the CP, AP, BC of the CML, the CML which gets the MCyR and the diabetes. Utility weight was developed using the EQ-5D method. All statistical data were analyzed by STATA 10.0 Results: 57 nurses(95%) out of 60 answered the questionnaire. In CP, the utility weight was 0.7946. In AP, it was 0.5301. and in BC, it was -0.2793. Survey data indicate that the worse the condition of a disease, the lower the utility weight. In case of the CML which gets the MCyR, the result was 0.7731(95% CI : 0.7384 - 0.8079). The general diabetes which has no complicating disease, the utility weight was 0.7481(95% CI : 0.6983 - 0.7978). Based on the result, it is evident that those with MCyR are not significantly different from people with general diabetes (p=0.4096) in views of the quality of life.

키워드

참고문헌

  1. 김동욱, 김춘추. 만성골수성백혈병 2003.
  2. 성주명. 백혈병 클리닉 2007.
  3. 한림의대 가정의학교실 편. 삶의 질 측정의 이론과 실제 1999.
  4. 의약품 경제성평가지침 및 자료작성 요령. 건강보험심사평가원 2007.
  5. Michael F. Drummond, Mark J. Sculpher, George W. Torrance, Bernie J. O`Brien, Greg L. Stoddart : Methods for the Economic Evaluation of Health Care Programmes (2006).
  6. Kim MH, CHo YS, Uhm WS, Kim SH, Bae SC. "Crosscultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases", Quality of Life Research 14(5), 2005, pp.1401-1406. https://doi.org/10.1007/s11136-004-5681-z
  7. Schrover RJ, Adena MA, De Abreu Lourenco R, Prince HM, Seymour JF, Wonder MJ. Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase. Leuk Lymphoma. 2006 Jun;47(6):1069-81. https://doi.org/10.1080/10428190500473055
  8. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi - Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2007 Dec 17.
  9. 최명애, 홍영숙, 박미정, 최스미, 이경숙, 서화숙, 신기수.병태생리학. 2001.
  10. Professor Rudy W.Bilous. 당뇨병 2005.
  11. Dolan, P., Gudex, C., Kind, P., Williams, A. A social tariff for EuroQol: Results from a UK general population survey. Centre for Health Economics, University of York. 1995.
  12. 임승지, 박형무, 강혜영, 이병석, 강영주, 신동혁. 시간교환법과 시각화 측정을 이용한 폐경후 에스트로겐 결핍증에 대한 효용분석. 보건행정학회지 2007년 17권 4호 113-133.
  13. Delziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukemia. Pharmacoeconomics. 2005;23(5):515- 26. https://doi.org/10.2165/00019053-200523050-00010
  14. Reed SD. Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004 Dec 1;101(11):2574-83. https://doi.org/10.1002/cncr.20694
  15. Druker BJ. Perspectives on the development of a molecularly targeted agent, Cancer Cell, 2002 Feb;1(1):31- 6. https://doi.org/10.1016/S1535-6108(02)00025-9